IN2014DN08830A - - Google Patents

Download PDF

Info

Publication number
IN2014DN08830A
IN2014DN08830A IN8830DEN2014A IN2014DN08830A IN 2014DN08830 A IN2014DN08830 A IN 2014DN08830A IN 8830DEN2014 A IN8830DEN2014 A IN 8830DEN2014A IN 2014DN08830 A IN2014DN08830 A IN 2014DN08830A
Authority
IN
India
Prior art keywords
eliciting
immune response
compositions
useful
individual
Prior art date
Application number
Other languages
English (en)
Inventor
Richard C Duke
Alex Franzusoff
Aurelia Haller
Thomas H King
Yingnian Lu
Victoria Kelley Hodson
Original Assignee
Globeimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Globeimmune Inc filed Critical Globeimmune Inc
Publication of IN2014DN08830A publication Critical patent/IN2014DN08830A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
IN8830DEN2014 2006-02-02 2007-02-02 IN2014DN08830A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76502506P 2006-02-02 2006-02-02
PCT/US2007/061572 WO2007092792A2 (fr) 2006-02-02 2007-02-02 Vaccin à base de levure destiné à induire une réponse immunitaire

Publications (1)

Publication Number Publication Date
IN2014DN08830A true IN2014DN08830A (fr) 2015-07-10

Family

ID=38345897

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8830DEN2014 IN2014DN08830A (fr) 2006-02-02 2007-02-02

Country Status (14)

Country Link
US (2) US7736642B2 (fr)
EP (2) EP1988919A4 (fr)
JP (3) JP5198290B2 (fr)
KR (2) KR101492524B1 (fr)
CN (2) CN104826102A (fr)
AU (1) AU2007212076B2 (fr)
BR (1) BRPI0706913A2 (fr)
CA (1) CA2638815A1 (fr)
IL (2) IL193196A (fr)
IN (1) IN2014DN08830A (fr)
MX (1) MX2008009929A (fr)
SG (2) SG10201402236VA (fr)
TW (2) TW201412329A (fr)
WO (1) WO2007092792A2 (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002039951A2 (fr) * 2000-11-15 2002-05-23 Globe Immune, Inc. Vaccins a base de cellules dendritiques et de levure, et leurs utilisations
JP4914990B2 (ja) * 2002-12-16 2012-04-11 グローブイミューン，インコーポレイテッド 動物を癌から守るための治療用組成物
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
WO2007008780A2 (fr) * 2005-07-11 2007-01-18 Globeimmune, Inc. Compositions et procedes permettant d'eliciter une reponse immune a des mutants d'echappement de therapies ciblees
US20070172503A1 (en) * 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
TW201412329A (zh) * 2006-02-02 2014-04-01 Globeimmune Inc 用於誘發免疫反應之以酵母菌爲基礎之疫苗
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
US9101578B2 (en) * 2006-05-01 2015-08-11 Technovax, Inc. Polyvalent influenza virus-like particle (VLP) compositions
EP1998814A4 (fr) * 2006-05-11 2010-06-16 Novavax Inc Nouveaux vaccins contre l'influenza m2
US9511134B2 (en) * 2006-05-18 2016-12-06 Epimmune Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
JP5570819B2 (ja) * 2007-02-02 2014-08-13 グローブイミューン，インコーポレイテッド 酵母を含む組成物および酵母を増殖させる方法
MX2009010066A (es) * 2007-03-19 2009-10-12 Globeimmune Inc Composiciones y metodos para la ablacion especifica de la evasion mutacional de terapias especificas para cancer.
US20100285050A1 (en) 2007-10-05 2010-11-11 Isis Innovation Limited Compositions and Methods
GB0719526D0 (en) * 2007-10-05 2007-11-14 Isis Innovation Compositions and methods
US20110177122A1 (en) * 2008-09-26 2011-07-21 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services Dna prime/activated vaccine boost immunization to influenza virus
KR102019728B1 (ko) 2009-04-17 2019-09-09 글로브이뮨 암에 대한 병용 면역요법 조성물 및 방법
WO2010134094A1 (fr) * 2009-05-18 2010-11-25 Panacea Biotec Ltd Vaccin universel contre la grippe basé sur un virus recombinant de la vaccine de souche modifiée ankara (mva)
EP2477647B1 (fr) 2009-09-14 2016-01-13 The Regents of the University of Colorado Modulation de produits d'immunothérapie à base de levure et réponses associées
US20120015346A1 (en) * 2010-07-08 2012-01-19 New York Medical College Influenza virus detection and diagnosis
RU2663718C2 (ru) * 2010-10-04 2018-08-08 Массачусетс Инститьют Оф Текнолоджи Полипептиды гемагглютининов, а также связанные с ними реагенты и способы
AU2011316164B2 (en) * 2010-10-15 2016-01-14 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara (MVA) influenza vaccine
EP2651439B1 (fr) 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions et procédés pour le traitement ou la prévention d'une infection par l'adénovirus 36 humain
WO2012106231A2 (fr) * 2011-01-31 2012-08-09 Baxter International Inc. Vecteurs viraux recombinants et procédés d'induction d'une réponse immunitaire hétéro sous-typique aux virus de la grippe a
SG192285A1 (en) 2011-02-12 2013-09-30 Globeimmune Inc Yeast-based therapeutic for chronic hepatitis b infection
HUE033491T2 (en) 2011-03-17 2017-12-28 Globeimmune Inc Yeast-Brachyury immunotherapy
US20140377295A1 (en) * 2011-05-23 2014-12-25 The Wistar Institute Of Anatomy And Biology Influenza vaccines containing modified adenovirus vectors
SG10201605265TA (en) * 2011-06-14 2016-08-30 Globeimmune Inc Yeast-Based Compositions and Methods for the Treatment or Prevention of Hepatitis Delta Virus Infection
WO2012177760A1 (fr) * 2011-06-20 2012-12-27 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Antigènes réactifs à large spectre optimisés par le calcul pour le virus de la grippe h1n1
CA2844500C (fr) 2011-08-17 2022-05-10 Globeimmune, Inc. Compositions immunotherapeutiques de -muc1 de levure et leurs utilisations
ES2525205T3 (es) * 2011-11-09 2014-12-18 Werner Lubitz Vacuna para su uso en inmunoterapia tumoral
DE102011121069A1 (de) * 2011-12-13 2013-06-13 Martin-Luther-Universität Halle-Wittenberg Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene
AU2013281221B2 (en) 2012-06-26 2018-05-17 Biodesix, Inc. Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
US9744193B2 (en) 2012-09-06 2017-08-29 Orbis Health Solutions Llc Tumor lysate loaded particles
JP5954079B2 (ja) 2012-09-25 2016-07-20 ソニー株式会社 培養観察装置及び培養観察方法
EP2929351B1 (fr) * 2012-12-10 2019-10-09 The University of Queensland Compositions de biofragments sans cellules, et systèmes, dispositifs et procédés correspondants
AU2014235120B2 (en) * 2013-03-15 2017-01-05 The Trustees Of The University Of Pennsylvania Vaccines having an antigen and interleukin-23 as an adjuvant
MX2015013380A (es) 2013-03-19 2016-01-08 Globeimmune Inc Inmunoterapia para cordoma a base de levadura.
TWI728239B (zh) 2013-03-26 2021-05-21 美商環球免疫公司 治療或預防人類免疫缺乏病毒感染之組合物及方法
JP2014210747A (ja) * 2013-04-19 2014-11-13 アンジェスＭｇ株式会社 細胞性免疫誘導能が改善された経口ワクチン
TWI654200B (zh) * 2013-08-30 2019-03-21 環球免疫公司 治療或預防結核病的組合物及方法
EP3092004A4 (fr) 2014-01-06 2017-02-22 The Trustees Of The University Of Pennsylvania Anticorps pd1 et pdl1 et combinaisons de vaccin et utilisation de celles-ci pour l'immunothérapie
CN106456532B (zh) 2014-03-05 2020-07-24 奥比思健康解决方案有限责任公司 使用酵母细胞壁颗粒的疫苗递送系统
AU2015243256B2 (en) * 2014-04-11 2020-11-05 Globeimmune, Inc. Yeast-based immunotherapy and type I interferon sensitivity
CN105233302B (zh) * 2014-07-10 2018-10-19 中国人民解放军军事医学科学院生物工程研究所 一种流感血凝素糖蛋白多聚物纳米颗粒的制备方法
CN107530383A (zh) 2015-01-09 2018-01-02 埃图比克斯公司 用于埃博拉病毒疫苗接种的方法和组合物
WO2016168187A1 (fr) * 2015-04-13 2016-10-20 The Regents Of The University Of Michigan Particules de type virus
CA2994272C (fr) 2015-08-03 2023-08-22 Globeimmune, Inc. Compositions immunotherapeutiques de levure brachyury modifiee
CN108367060B (zh) * 2015-08-11 2022-07-19 奥比思健康解决方案有限责任公司 细菌和病毒疫苗策略
GB2552441A (en) * 2015-10-22 2018-01-31 Royal Veterinary College Methods
EP3195878A1 (fr) 2016-01-22 2017-07-26 Werner Lubitz Hôtes bactériens pour le traitement du cancer
CA3018741A1 (fr) 2016-03-24 2017-12-28 Nantcell, Inc. Arrangements de sequences et sequences pour la presentation de neo-epitopes
KR102306403B1 (ko) 2017-04-24 2021-09-28 난트셀, 인크. 표적화된 네오에피토프 벡터 및 그에 관한 방법 (targeted neoepitope vectors and methods therefor)
CN111556896A (zh) * 2017-12-21 2020-08-18 株式会社绿色生物医药 交叉免疫抗原疫苗及其制备方法
DE102017012109A1 (de) 2017-12-27 2019-06-27 Martin-Luther-Universität Halle-Wittenberg Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis
US20210154250A1 (en) 2018-05-15 2021-05-27 Globeimmune, Inc. Lysates of recombinant yeast for inducing cellular immune responses
WO2020051766A1 (fr) 2018-09-11 2020-03-19 上海市公共卫生临床中心 Immunogène pour vaccin à large spectre contre la grippe, et application de celui-ci
US20210290708A1 (en) 2018-09-21 2021-09-23 Nantcell, Inc. Methods and compositions for modulating myeloid-derived suppressor cells
CN114269374A (zh) * 2019-05-21 2022-04-01 艾斯佩罗疫苗公司 基于酵母的口服疫苗接种
WO2021163222A1 (fr) * 2020-02-11 2021-08-19 Cytonus Therapeutics, Inc. Plate-forme de vaccin rapide
US11857620B2 (en) 2020-03-11 2024-01-02 Immunitybio, Inc. Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
WO2021211691A1 (fr) 2020-04-14 2021-10-21 Immunitybio, Inc. Vaccin contre la covid-19 à base de lysat de levure

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5830463A (en) * 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
WO1995018861A1 (fr) 1994-01-11 1995-07-13 Vlaams Interuniversitair Instituut Voor Biotechnologie Vaccin contre la grippe
US5691189A (en) * 1994-01-19 1997-11-25 Bristol-Myers Squibb Company Saccharomyces cerevisiae expressing M2 protein of influenza A virus
US6696251B1 (en) * 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US20020044948A1 (en) * 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
ATE376059T1 (de) * 2000-06-23 2007-11-15 Wyeth Corp Assemblierung von wildtyp und chimären influenzavirus-ähnlichen partikeln (vlps)
WO2002039951A2 (fr) * 2000-11-15 2002-05-23 Globe Immune, Inc. Vaccins a base de cellules dendritiques et de levure, et leurs utilisations
US20030008000A1 (en) 2001-03-08 2003-01-09 Wong Jonathan P. DNA vaccine using liposome-encapsulated plasmid DNA encoding for hemagglutinin protein of influenza virus
US20030202982A1 (en) * 2001-08-15 2003-10-30 Birkett Ashley J. Influenza immunogen and vaccine
JP4914990B2 (ja) * 2002-12-16 2012-04-11 グローブイミューン，インコーポレイテッド 動物を癌から守るための治療用組成物
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
JP5331340B2 (ja) * 2004-05-18 2013-10-30 バイカル インコーポレイテッド インフルエンザウィルスワクチン組成物、及びその使用方法
JP5302537B2 (ja) 2004-09-17 2013-10-02 ユニバーシティ オブ マサチューセッツ リソソーム酵素欠損症のための組成物およびそれらの使用
TW201412329A (zh) * 2006-02-02 2014-04-01 Globeimmune Inc 用於誘發免疫反應之以酵母菌爲基礎之疫苗

Also Published As

Publication number Publication date
CN101405026A (zh) 2009-04-08
CA2638815A1 (fr) 2007-08-16
SG169375A1 (en) 2011-03-30
US20080003239A1 (en) 2008-01-03
IL193196A (en) 2015-01-29
AU2007212076A1 (en) 2007-08-16
MX2008009929A (es) 2008-10-01
US7736642B2 (en) 2010-06-15
AU2007212076B2 (en) 2012-10-18
JP2015038147A (ja) 2015-02-26
CN101405026B (zh) 2015-04-22
EP2468296A3 (fr) 2013-12-04
WO2007092792A2 (fr) 2007-08-16
US20100196411A1 (en) 2010-08-05
TW201412329A (zh) 2014-04-01
EP2468296A2 (fr) 2012-06-27
BRPI0706913A2 (pt) 2011-04-12
JP2013075899A (ja) 2013-04-25
JP5198290B2 (ja) 2013-05-15
IL193196A0 (en) 2011-08-01
JP2009528987A (ja) 2009-08-13
KR20140029551A (ko) 2014-03-10
WO2007092792A3 (fr) 2008-02-28
KR20080089671A (ko) 2008-10-07
CN104826102A (zh) 2015-08-12
EP1988919A4 (fr) 2009-06-10
EP1988919A2 (fr) 2008-11-12
SG10201402236VA (en) 2014-08-28
KR101492524B1 (ko) 2015-02-12
IL232518A0 (en) 2014-06-30
TW200806316A (en) 2008-02-01

Similar Documents

Publication Publication Date Title
IN2014DN08830A (fr)
WO2007024941A3 (fr) Vaccin polyvalent
AU2009326524A8 (en) Use of Flt3 ligand for strengthening immune responses in RNA immunization
MXPA05013973A (es) Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos.
WO2010019262A3 (fr) Vaccin polyvalent
WO2007120673A3 (fr) Peptides wt1 immunogènes et leurs méthodes d'utilisation
MX2019011253A (es) Composiciones adyuvantes novedosas.
TNSN07387A1 (en) C.perfringens alpha toxoid vaccine
SG158154A1 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
WO2006068663A3 (fr) Compositions de vaccin et procedes permettant de traiter des infections par coronavirus
MX2010012999A (es) Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso.
WO2016019134A8 (fr) Agents à base de flagelline et utilisations comportant une vaccination efficace
WO2006113214A3 (fr) Vaccin contre des souches pandemiques des virus de la grippe
WO2008148057A3 (fr) Compositions et procédés pour améliorer la réponse immunitaire à des vaccins
PH12015501637A1 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
IN2014DN09791A (fr)
CA2763359C (fr) Nouvelles souches de rotavirus humain et nouveaux vaccins
WO2009135199A3 (fr) Compositions vaccinales et procédés
AU2007272785A8 (en) Methods to elicit, enhance and sustain immune responses against MHC class-I restricted epitopes, for prophylactic or therapeutic purposes
GB2444676A (en) Adjuvanted vaccine
WO2011074006A3 (fr) Composition de vaccin
WO2007120603A3 (fr) Peptides bcr-abl immunogènes et leurs méthodes d'utilisation
WO2010080188A3 (fr) Vaccin ciblé par épitope contre le charbon
WO2007028985A3 (fr) Vaccin contenant un adjuvant
WO2007120860A3 (fr) Vaccins à base d'une nanoémulsion